



Balfour Capital Group Abbott Laboratories

Abbott Laboratories is a global healthcare company that develops, manufactures, and markets a wide range of medical products and services. Its diversified portfolio includes diagnostics, medical devices, nutritionals, and branded generic pharmaceuticals, serving customers in more than 160 countries. Abbott is known for innovations such as the FreeStyle Libre glucose monitoring system and structural heart devices.

1. Top 5 Competitors

Abbott's primary competitors in the healthcare sector include:

1. Johnson & Johnson
2. Medtronic
3. Pfizer
4. Roche
5. Boston Scientific

These companies compete across various segments such as medical devices, diagnostics, and pharmaceuticals.

2. Largest Institutional Shareholders

As of December 31, 2024, the largest institutional shareholders of Abbott Laboratories are:

- The Vanguard Group, Inc.: 9.72% ownership (168.6 million shares)
- BlackRock, Inc.: 7.86% ownership (136.3 million shares)
- Capital Research and Management Company: 7.25% ownership
- State Street Global Advisors, Inc.: 4.45% ownership
- Geode Capital Management, LLC: 2.06% ownership

3. Management Team:

Key members of Abbott's executive leadership include:

- Robert B. Ford: Chairman and Chief Executive Officer
- Phil Boudreau: Senior Vice President, Finance, and Chief Financial Officer
- Daniel Salvadori: Executive Vice President and Group President, Established Pharmaceuticals and Nutritional Products
- Hubert Allen: Executive Vice President, General Counsel, and Secretary



Balfour Capital Group Abbott Laboratories

4. Revenue

For the fiscal year 2024, Abbott Laboratories reported:

- Total Revenue: \$41.95 billion, a 4.59% increase from 2023
- Q1 2025 Revenue: \$10.36 billion, a 4% year-over-year increase

5. Institutions with Buy Recommendations:

Several financial institutions have issued buy recommendations for Abbott Laboratories, including:

- Citigroup: Maintains Buy rating with a price target of \$155
- Goldman Sachs: Maintains Buy rating with a price target of \$147
- Bank of America: Raised price target to \$150
- Raymond James: Outperform rating with a price target of \$142
- RBC Capital Markets: Outperform rating with a price target of \$145

6. Summary of Analyst Sentiment:

Analyst consensus indicates a positive outlook for Abbott Laboratories:

- Consensus Rating: Moderate Buy
- Average Price Target: \$144.82, with a high estimate of \$160 and a low of \$135
- Earnings Forecast: Adjusted EPS for 2025 projected between \$5.05 and \$5.25

7. Insider Buying and Selling Over the Last 24 Months:

Over the past 24 months, insider trading activity at Abbott Laboratories includes:

- Shares Sold: 531,165 shares, totaling approximately \$61.46 million
- Recent Activity: In the last 6 months, there have been 15 insider sales and no purchases